Generic Medicines: Solutions for a Sustainable Drug Market? Pieter DylstArnold VultoSteven Simoens Current Opinion 12 July 2013 Pages: 437 - 443
Systematic Review of Drug Administration Costs and Implications for Biopharmaceutical Manufacturing Ebenezer TettehStephen Morris Systematic Review 12 July 2013 Pages: 445 - 456
Cost Effectiveness of Romiplostim for the Treatment of Chronic Immune Thrombocytopenia in Ireland Dawn LeePatrick ThorntonNic Brereton Original Research Article Open access 16 July 2013 Pages: 457 - 469
Does the Type of Provider and the Place of Residence Matter in the Utilization of Prenatal Ultrasonography? Evidence from Canada Harminder GulianiArdeshir SepehriJohn Serieux Original Research Article 03 August 2013 Pages: 471 - 484
Cost Effectiveness of Denosumab versus Oral Bisphosphonates for Postmenopausal Osteoporosis in the US Anju ParthanMorgan KruseDouglas Taylor Original Research Article 19 July 2013 Pages: 485 - 497
Preferences for Colorectal Cancer Screening Techniques and Intention to Attend: a Multi-Criteria Decision Analysis J. Marjan HummelLotte G. M. SteutenMaarten J. IJzerman Original Research Article 24 August 2013 Pages: 499 - 507
Cost Effectiveness of Paliperidone Palmitate for the Treatment of Schizophrenia in Germany Jan ZeidlerJörg MahlichStephan Heres Original Research Article 22 August 2013 Pages: 509 - 521
Private Expenditures on Brand Name Prescription Drugs after Generic Entry Dahlia Y. BalabanIrfan A. DhallaChaim M. Bell Original Research Article 27 August 2013 Pages: 523 - 529
Economic Evaluation of Cardio inCode®, a Clinical-Genetic Function for Coronary Heart Disease Risk Assessment A. Ramírez de ArellanoA. CocaE. Salas Original Research Article Open access 28 September 2013 Pages: 531 - 542
Evolutions in Both Co-Payment and Generic Market Share for Common Medication in the Belgian Reference Pricing System Jessica FraeymanMoira VerbelenPhilippe Beutels Original Research Article 06 September 2013 Pages: 543 - 552
Comment on: “Cost-Utility Analysis of Duloxetine in Osteoarthritis: A US Private Payer Perspective” Hiltrud LiedgensRainer Henske Letter to the Editor Open access 06 August 2013 Pages: 553 - 554
Authors’ Reply to Liedgens and Henske: “Cost-Utility Analysis of Duloxetine in Osteoarthritis: A US Private Payer Perspective” Ronald C. WielageMegha BansalMichael Happich Letter to the Editor 02 August 2013 Pages: 555 - 557